查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
美國靜脈注射免疫球蛋白市場預測至2028年 - 按類型、應用、配銷通路和終端用戶分類的COVID-19影響和國家分析
市場調查報告書
商品編碼
1280763

美國靜脈注射免疫球蛋白市場預測至2028年 - 按類型、應用、配銷通路和終端用戶分類的COVID-19影響和國家分析

US Intravenous Immunoglobulin Market Forecast to 2028 - Country Analysis By Type, Application, Distribution Channel, and End User
出版日期: | 出版商: The Insight Partners | 英文 145 Pages | 訂單完成後即時交付

價格

美國靜脈免疫球蛋白市場規模在2022年為44.3926億美元，預計到2028年將達到71.0563億美元；估計在2023-2028年期間將以復合年成長率8.2%成長。老年人口的增加有利於美國靜脈注射免疫球蛋白市場的成長。

免疫球蛋白是人體免疫系統自然產生的抗體，它有助於抵抗感染和疾病。患有免疫球蛋白缺乏症的人需要外用免疫球蛋白，稱為免疫球蛋白替代療法（IgRT）。 IgRT可以通過靜脈注射和皮下注射。靜脈注射免疫球蛋白（IVIg）和皮下注射免疫球蛋白（SCIg）是根據適應症和嚴重程度來選擇。 IVIgs是從人類血漿中提取的。這些抗體被用於治療各種免疫學、血液學和神經學疾病。美國的免疫缺陷病發病率上升和老年人口增加等因素推動了美國靜脈免疫球蛋白市場的成長。然而，免疫球蛋白治療的不良反應阻礙了市場的成長。

IVIGs用於治療原發性和繼發性免疫缺陷和自身免疫性疾病的患者。 IVIG是治療大多數原發性免疫缺陷（PID）的標準療法。根據約翰-霍普金斯醫學院的數據，美國總人口的約3%，即1000萬人，患有自身免疫性疾病。根據美國國家過敏和傳染病研究所（NIAID）的數據，有超過200種不同類型的原發性免疫缺陷病（PIDD）影響著美國約50萬人。這些罕見的遺傳性疾病可能是慢性的、衰弱的，而且治療費用昂貴。免疫性血小板減少症（ITP）是一種自身免疫性的出血性疾病，其特點是血小板水平異常低；這種情況被稱為血小板減少症。罕見病組織指出，在美國，成人ITP的發病率為每年每10萬人中約有3.3人。根據2019年發布的全國多發性硬化症協會研究報告，在美國，~100萬成年人（~913,925）受到多發性硬化症（MS）的影響。根據多發性硬化發現論壇，美國每周有~200個新病例被診斷出來。因此，免疫缺陷疾病發病率的增加推動了美國靜脈注射免疫球蛋白市場的成長。

許多在美國靜脈注射免疫球蛋白市場經營的市場參與者和研究機構正在開發先進的技術，以擴大他們的產品組合，增加他們的市場佔有率。免疫缺陷病發病率的上升、產品的批准和合作是推動美國靜脈免疫球蛋白市場規模的因素之一。

以下是與美國靜脈注射免疫球蛋白有關的一些最新發展：

2020年4月，Kamada Ltd.和Kedrion Biopharma合作開發、生產和銷售一種人類血漿衍生的抗SARS-CoV-2（COVID-19）多克隆免疫球蛋白（IgG）產品，作為對抗COVID-19的潛在治療方法。該公告是在這兩個實體之前關於啟動此類產品的開發計劃的單獨報告之後發布的。

2022年1月，LFB和Kedrion在一項工業合作協議中聯手，為法國的患者提供更多的免疫球蛋白。在這一工業合作框架下，Kedrion在匈牙利用LFB的血漿生產免疫球蛋白，這些血漿是由"法國血液公司"（EFS）在法國收集的。 LFB進口這些由Kedrion在法國製造的免疫球蛋白，並補充其免疫球蛋白，這些免疫球蛋白在法國各地的醫院都可以買到，並與法國衛生當局達成協議，受其管制。

2020年4月，2020年4月，Octapharma與CSL、武田、BPL、Biotest和LFB合作，研究用血漿衍生的超免疫免疫球蛋白治療COVID-19的可能性。

美國靜脈注射免疫球蛋白市場，以類型為基礎的洞察力

基於產品類型，美國靜脈注射免疫球蛋白市場被分類為IgG、IgM、IgA和其他。 2022年，IgG部分佔據了市場的最大佔有率。此外，在預測期內，該部分預計將錄得最高的複合年成長率。

IVIg是一種替代療法，用於治療抗體缺乏的病人或患有免疫缺陷疾病的病人。例如，在原發性或繼發性低丙種球蛋白血症中，IVIg替代療法通過在血液中註入足夠數量的IgG來提供保護，防止感染。 IVIg是一种血液製品，由每批1,000-15,000名獻血者的血清製備而成，其中只有IgG從血漿中純化出來，以生產IVIg產品。因此，用於治療療法的IVIg含有95-98%的純IgG和少量的其他血漿蛋白，包括IgA和IgM。

因此，IgG在治療幾類疾病中的廣泛應用是促進美國靜脈免疫球蛋白市場成長的因素之一。

美國靜脈注射免疫球蛋白市場，以終端用戶為基礎的洞察力

美國靜脈注射免疫球蛋白市場，基於終端用戶，分為低丙種球蛋白血症、慢性炎症性脫髓鞘多發性神經病（CIDP）、免疫缺陷病、重症肌無力（MG）、多灶性運動神經病（MMN）、特發性血小板減少性紫癜（ITP）、炎症性肌病、特定抗體缺乏（SDA）、吉蘭巴雷綜合症（GBS）和其他。 2022年，免疫缺陷病部分佔據了最大的市場佔有率，在。在未來幾年裡，同一細分市場預計將以最快的速度成長。

世界衛生組織（WHO）、美國人口普查局和美國國家醫學圖書館是編寫美國靜脈免疫球蛋白市場報告時參考的幾個主要主要和次要來源。

目錄

第一章：簡介

  • 本研究的範圍
  • Insight Partners的研究報告指導
  • 市場細分
    • 靜脈注射免疫球蛋白市場- 按類型分類
    • 靜脈注射免疫球蛋白市場- 按應用分類
    • 靜脈注射免疫球蛋白市場- 按銷售管道分類
    • 靜脈注射免疫球蛋白市場- 按終端用戶分類
    • 靜脈注射免疫球蛋白市場- 按國家分類

第二章：靜脈注射免疫球蛋白市場- 主要收穫

第三章：研究方法

  • 涵蓋範圍
  • 二級研究
  • 初級研究

第四章：靜脈注射免疫球蛋白市場- 市場格局

  • 概述
  • PEST分析
    • 美國- PEST分析
  • 專家意見
  • 管線產品

第五章：美國靜脈注射免疫球蛋白市場- 主要市場動態

  • 市場驅動力
    • 免疫缺陷病發病率的上升
    • 老年人口不斷增加
  • 市場限制因素
    • 免疫球蛋白治療的不良反應
  • 市場機會
    • 繁榮的製藥業
  • 未來趨勢
    • 強大的IVIG候選產品管道
  • 影響分析

第六章：靜脈注射免疫球蛋白市場- 美國分析

  • 美國靜脈注射免疫球蛋白市場收入預測和分析
  • 主要參與者的市場定位

第七章：美國靜脈注射免疫球蛋白市場分析- 按類型分類

  • 概述
  • 美國靜脈注射免疫球蛋白市場，按類型分類- 2028年的數量和預測（公噸）
  • IgG
  • IgM
  • IgA
  • 其他類型

第八章：美國靜脈注射免疫球蛋白市場分析- 按應用分類

  • 概況
  • 低丙種球蛋白血症
  • 慢性炎症性脫髓鞘多發性神經病(CIPD)
  • 免疫缺陷性疾病
  • 重症肌無力症
  • 多灶性運動神經病變
  • 特發性血小板減少性紫癜
  • 炎症性肌病
  • 特異性抗體缺乏症
  • 吉蘭-巴雷症候群
  • 其他疾病

第九章：美國靜脈注射免疫球蛋白市場分析- 按銷售管道分類

  • 概述
  • 醫院藥房
  • 零售藥店
  • 其他管道

第十章: 美國靜脈注射免疫球蛋白市場分析- 按終端用戶分類

  • 概述
  • 醫院
  • 專業診所
  • 其他

第十一章：美國靜脈注射免疫球蛋白市場

  • 美國

第十二章：美國靜脈注射免疫球蛋白市場- 行業格局

  • 概述
  • 美國靜脈注射免疫球蛋白市場的成長策略（%）。
  • 有機發展
    • 概述
  • 無機發展
    • 縱覽

第十三章：公司簡介

  • Takeda Pharmaceutical Co Ltd
  • Grifols SA
  • Pfizer Inc
  • ADMA Biologics, Inc.
  • Bio Products Laboratory Ltd.
  • Octapharma AG
  • Kedrion SpA
  • CSL Ltd
  • LFB Group
  • Prothya Biosolutions BV

第十四章：附錄

  • 關於洞察力合作夥伴
  • 術語表
Product Code: TIPRE00029893

The US intravenous immunoglobulin market size was valued at US$ 4,439.26 million in 2022 and is projected to reach US$ 7,105.63 million by 2028; it is estimated to grow at a CAGR 8.2% during 2023-2028. The increasing geriatric population favors the growth of the US intravenous immunoglobulin market.

Immunoglobulins are the antibodies produced naturally by the body's immune system, which help fight infection and disease. Individuals with immunoglobulin deficiency require the external administration of immunoglobulin and known as immunoglobulin replacement therapy (IgRT). IgRT can be given intravenously and subcutaneously. Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) are selected based on the indication and severity. IVIgs are extracted from human plasma. These antibodies are used in the treatment of various immunological, hematological, and neurological illnesses. Factors such as rising immunodeficiency disease prevalence and increasing geriatric population in the US drive the US intravenous immunoglobulin market growth. However, adverse effects of immunoglobulin therapy hamper the market growth.

IVIGs are used to treat patients suffering from primary and secondary immunodeficiencies and autoimmune disorders. The IVIG is a standard therapy to treat most primary immunodeficiencies (PIDs). According to data by John Hopkins Medicine, ~3% of the total US population, i.e., 10 million people, suffers from autoimmune diseases. As per the National Institute of Allergy and Infectious Diseases (NIAID), there are over 200 different types of primary immune deficiency diseases (PIDDs) affecting ~500,000 people in the US. The rare genetic diseases can be chronic, weakening, and expensive to treat. Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of platelets; a situation referred to as thrombocytopenia. The Rare Diseases Organization states that the incidence rate of ITP in adults is ~3.3 per 100,000 per year in the US. Per the National Multiple Sclerosis Society study report, published in 2019, ~1 million adults (~913,925) were affected by multiple sclerosis (MS) in the US. According to the MS Discovery Forum, ~200 new cases are diagnosed each week in the US. Thus, the increasing prevalence of immunodeficiency diseases drives the growth of the US intravenous immunoglobulin market.

Many market players and research institutes operating in the US intravenous immunoglobulin market are developing advanced technologies to expand their product portfolios and increase their market shares. Rising immunodeficiency disease prevalence, product approvals, and collaborations are among the factors driving the US intravenous immunoglobulin market size.

A few of the recent developments related to US intravenous immunoglobulin are mentioned below:

In April 2020, Kamada Ltd. and Kedrion Biopharma collaborated to develop, manufacture, and distribute a human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment against COVID-19. The announcement follows separate previous reports by the two entities concerning initiating development programs for such products.

In January 2022, LFB and Kedrion joined forces in an industrial cooperation agreement to increase the availability of immunoglobulins for patients in France. In the framework of this industrial partnership, Kedrion manufactured immunoglobulins in Hungary from LFB plasma which was collected in France by the "Etablissement Francais du Sang" (EFS). LFB imported these immunoglobulins manufactured by Kedrion in France and complemented its immunoglobulins, which are available in hospitals across France, in agreement with and under the control of French health authorities.

In April 2020, In April 2020, Octapharma collaborated with CSL, Takeda, BPL, Biotest, and LFB to investigate the possibility of treating COVID-19 with plasma-derived hyperimmune immunoglobulins.

US Intravenous Immunoglobulin Market, By Type-Based Insights

Based on product type, the US intravenous immunoglobulin market is segmented into IgG, IgM, IgA, and others. In 2022, the IgG segment held the largest share of the market. Moreover, the same segment is expected to record the highest CAGR during the forecast period.

IVIg is a replacement therapy and treatment for patients with antibody deficiencies or for those who suffer from immunodeficiency disorders. For instance, in primary or secondary hypogammaglobulinemia, IVIg replacement therapy provides protection against infections by administering an adequate volume of IgG in the blood. IVIg is a blood product prepared from serum derived from 1,000-15,000 donors per batch where only IgG is purified from plasma to produce IVIg products. Therefore, IVIg used for treatment therapies contains 95-98% pure IgG with small amounts of other plasma proteins, including IgA and IgM.

Thus, wide applications of IgG in treating several categories of disorders are among the factors contributing to the growth of the US intravenous immunoglobulin market.

US Intravenous Immunoglobulin Market, By End User-Based Insights

The US intravenous immunoglobulin market, based on end user, is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. In 2022, the immunodeficiency diseases segment held the largest market share in . The same segment is expected to grow at the fastest rate during the coming years.

The World Health Organization (WHO), the US Census Bureau, and the US National Library of Medicine are a few of the major primary and secondary sources referred to while preparing the report on the US intravenous immunoglobulin market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the US intravenous immunoglobulin market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the US intravenous immunoglobulin market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth Germany market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Intravenous Immunoglobulin Market - By Type
    • 1.3.2 Intravenous Immunoglobulin Market - By Application
    • 1.3.3 Intravenous Immunoglobulin Market - By Distribution Channel
    • 1.3.4 Intravenous Immunoglobulin Market - By End User
    • 1.3.5 Intravenous Immunoglobulin Market - By Country

2. Intravenous Immunoglobulin Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Intravenous Immunoglobulin Market - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 US - PEST Analysis
  • 4.3 Expert Opinion
  • 4.4 Pipeline Product

5. United States Intravenous Immunoglobulin Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Immunodeficiency Disease Prevalence
    • 5.1.2 Increasing Geriatric Population
  • 5.2 Market Restraints
    • 5.2.1 Adverse Effects of Immunoglobulin Therapy
  • 5.3 Market Opportunities
    • 5.3.1 Flourishing Pharmaceutical Industry
  • 5.4 Future Trends
    • 5.4.1 Strong Pipeline of IVIG Candidates
  • 5.5 Impact Analysis

6. Intravenous Immunoglobulin Market - US Analysis

  • 6.1 United States Intravenous Immunoglobulin Market Revenue Forecast and Analysis
  • 6.2 Market Positioning of Key Players

7. United States Intravenous Immunoglobulin Market Analysis - by Type

  • 7.1 Overview
  • 7.2 United States Intravenous Immunoglobulin Market, by Type - Volume and Forecast to 2028 (Metric Tons)
  • 7.3 United States Intravenous Immunoglobulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 IgG
    • 7.4.1 Overview
    • 7.4.2 IgG: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 IgM
    • 7.5.1 Overview
    • 7.5.2 IgM: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.6 IgA
    • 7.6.1 Overview
    • 7.6.2 IgA: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)

8. United States Intravenous Immunoglobulin Market Analysis - by Application

  • 8.1 Overview
  • 8.2 United States Intravenous Immunoglobulin Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • 8.3 Hypogammaglobulinemia
    • 8.3.1 Overview
    • 8.3.2 Hypogammaglobulinemia: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Chronic Inflammatory Demyelinating Polyneuropathy (CIPD)
    • 8.4.1 Overview
    • 8.4.2 CIPD: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.5 Immunodeficiency Diseases
    • 8.5.1 Overview
    • 8.5.2 Immunodeficiency Disease: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.6 Myasthenia Gravis
    • 8.6.1 Overview
    • 8.6.2 Myasthenia Gravis: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.7 Multifocal Motor Neuropathy
    • 8.7.1 Overview
    • 8.7.2 Multifocal Motor Neuropathy: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.8 Idiopathic Thrombocytopenic Purpura
    • 8.8.1 Overview
    • 8.8.2 Idiopathic Thrombocytopenic Purpura: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.9 Inflammatory Myopathies
    • 8.9.1 Overview
    • 8.9.2 Inflammatory Myopathies: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.10 Specific Antibody Deficiency
    • 8.10.1 Overview
    • 8.10.2 Specific Antibody Deficiency: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.11 Guillain-Barre Syndrome
    • 8.11.1 Overview
    • 8.11.2 Guillain-Barre Syndrome: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.12 Others
    • 8.12.1 Overview
    • 8.12.2 Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)

9. United States Intravenous Immunoglobulin Market Analysis - by Distribution Channel

  • 9.1 Overview
  • 9.2 United States Intravenous Immunoglobulin Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • 9.3 Hospital Pharmacy
    • 9.3.1 Overview
    • 9.3.2 Hospital Pharmacy: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.4 Retail Pharmacy
    • 9.4.1 Overview
    • 9.4.2 Retail Pharmacy: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.5 Others
    • 9.5.1 Overview
    • 9.5.2 Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)

10. United States Intravenous Immunoglobulin Market Analysis - by End User

  • 10.1 Overview
  • 10.2 United States Intravenous Immunoglobulin Market, by End User - Revenue and Forecast to 2028 (US$ Million)
  • 10.3 Hospitals
    • 10.3.1 Overview
    • 10.3.2 Hospitals: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.4 Specialty Clinics
    • 10.4.1 Overview
    • 10.4.2 Specialty Clinics: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.5 Others
    • 10.5.1 Overview
    • 10.5.2 Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)

11. United States Intravenous Immunoglobulin Market: Impact Assessment of COVID-19 Pandemic

  • 11.1 US: Impact Assessment of COVID-19 Pandemic

12. US Intravenous Immunoglobulin Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in US Intravenous Immunoglobulin Market (%)
  • 12.3 Organic Developments
    • 12.3.1 Overview
  • 12.4 Inorganic Developments
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Takeda Pharmaceutical Co Ltd
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Grifols SA
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Pfizer Inc
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 ADMA Biologics, Inc.
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Bio Products Laboratory Ltd.
        • 13.5.1.1.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Octapharma AG
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Kedrion SpA
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 CSL Ltd
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 LFB Group
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Prothya Biosolutions B.V.
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms

List Of Tables

  • Table 1. Pipeline Product Developments in the US Intravenous Immunoglobulin Market
  • Table 2. R&D Investments by Major Pharmaceuticals Companies in US
  • Table 3. United States Intravenous Immunoglobulin Market, by Type - Volume and Forecast to 2028 (Metric Tons)
  • Table 4. United States Intravenous Immunoglobulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. United States Intravenous Immunoglobulin Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 6. United States Intravenous Immunoglobulin Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 7. United States Intravenous Immunoglobulin Market, by End User - Revenue and Forecast to 2028 (US$ Million)
  • Table 8. Organic Developments in the US Intravenous Immunoglobulin Market
  • Table 9. Inorganic Developments in the US Intravenous Immunoglobulin Market
  • Table 10. Glossary of Terms

List Of Figures

  • Figure 1. Intravenous Immunoglobulin Market Segmentation
  • Figure 2. United States Intravenous Immunoglobulin Market Overview
  • Figure 3. IgG Held Largest Share of Intravenous Immunoglobulin Market
  • Figure 4. United States Intravenous Immunoglobulin Market, Industry Landscape
  • Figure 5. US PEST Analysis
  • Figure 6. Expert Opinion
  • Figure 7. US Intravenous Immunoglobulin Market Impact Analysis of Drivers and Restraints
  • Figure 8. United States Intravenous Immunoglobulin Market - Revenue Forecast and Analysis - 2020- 2028
  • Figure 9. Market Positioning of Key Players in United States Intravenous Immunoglobulin Market
  • Figure 10. United States Intravenous Immunoglobulin Market, by Type, 2022 & 2028 (%)
  • Figure 11. IgG: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 12. IgM: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 13. IgA: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 14. Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 15. United States Intravenous Immunoglobulin Market, by Application, 2022 & 2028 (%)
  • Figure 16. Hypogammaglobulinemia: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • Figure 17. CIPD: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • Figure 18. Immunodeficiency Disease: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • Figure 19. Myasthenia Gravis: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • Figure 20. Multifocal Motor Neuropathy: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • Figure 21. Idiopathic Thrombocytopenic Purpura: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • Figure 22. Inflammatory Myopathies: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 23. Specific Antibody Deficiency: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 24. Guillain-Barre Syndrome: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 25. Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 26. United States Intravenous Immunoglobulin Market, by Distribution Channel, 2022 & 2028 (%)
  • Figure 27. Hospital Pharmacy: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 28. Retail Pharmacy: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 29. Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 30. United States Intravenous Immunoglobulin Market, by End User, 2022 & 2028 (%)
  • Figure 31. Hospitals: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 32. Specialty Clinics: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 33. Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 34. Impact of COVID-19 Pandemic on US Intravenous Immunoglobulin Market
  • Figure 35. Growth Strategies in US Intravenous Immunoglobulin Market (%)